Dalton Launches Clinical Injectables Service
Dalton Pharma Services announced on Dec. 2, 2014 that it will launch “Steriles Made Simple” programs designed to produce clinical sterile liquid injectables faster. Dalton will use pre-prepared material, process, and systems to deliver cGMP sterile liquid injectables to customers within four months of available APIs, specifically small molecule Phase I/II projects requiring batches of 10,000 vials or less.
“We looked at the critical aspects of cGMP sterile vial manufacturing that resulted in the longest timelines and really simplified this complex process for our customers. Steriles Made Simple (SM) has been a strategic priority for Dalton with a focus on delivering product faster, without compromising the quality,” said Peter Pekos, CEO & president of Dalton Pharma Services, in a press release.
Source: Dalton Pharma Services
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
